Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.

about

Podocyte p53 Limits the Severity of Experimental Alport Syndrome.

P2860

Q36417903-4D584C95-8399-43ED-BAC8-56E73ED27E8D

P2860

Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.

Item

http://www.wikidata.org/entity/Q41365125

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cyclin-Dependent Kinase Activi ...... strointestinal Stromal Tumors.

@en

type

Item

label

Cyclin-Dependent Kinase Activi ...... strointestinal Stromal Tumors.

@en

prefLabel

Cyclin-Dependent Kinase Activi ...... strointestinal Stromal Tumors.

@en

P1476

Cyclin-Dependent Kinase Activi ...... strointestinal Stromal Tumors.

@en

P2093

Haruhiko Cho

http://www.w3.org/2001/XMLSchema#string

Hideki Ishihara

http://www.w3.org/2001/XMLSchema#string

Masahiko Tsujimoto

http://www.w3.org/2001/XMLSchema#string

Masahiro Yamamura

http://www.w3.org/2001/XMLSchema#string

Satoshi Nakayama

http://www.w3.org/2001/XMLSchema#string

Seiichi Hirota

http://www.w3.org/2001/XMLSchema#string

Shigeyuki Ueshima

http://www.w3.org/2001/XMLSchema#string

Takeshi Omori

http://www.w3.org/2001/XMLSchema#string

Tomoko Matsushima

http://www.w3.org/2001/XMLSchema#string

Toshirou Nishida

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle, CDKs and cancer: a changing paradigm

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Gastrointestinal stromal tumors: pathology and prognosis at different sites.

p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.

P2888

s10434-015-4438-y

P304

3565-3573

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-015-4438-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002517324

http://www.w3.org/2001/XMLSchema#string

P698

25707496

http://www.w3.org/2001/XMLSchema#string

Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.

about

P2860

P2860

Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698